ArticleBiomarker research2025
Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021.
Article in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of the prevalence of reflux symptoms after esophagectomy: patient-reported outcomes and management.BMC geriatrics · 2026Pooled it
- Machine learning applications in predicting pharmacological treatment outcomes and responses in esophageal cancer.Frontiers in pharmacology · 2026Pooled it
- HPV prevalence in esophageal cancer: an updated systematic review and meta-analysis.Frontiers in microbiology · 2026Pooled it
- Ivor Lewis minimally invasive oesophagectomy versus McKeown approach: short-term benefits and mid-term equivalence in a randomized trial for oesophageal squamous cell carcinoma.Surgical endoscopy · 2026Trial
- Global burden of esophageal cancer attributable to smoking and alcohol, 1990-2021, with projections to 2040: a population-based analysis of the global burden of disease study 2021.Annals of medicine · 2026Observational
- Applications of circulating tumor cells in esophageal cancer detection and treatment.Discover oncology · 2026Review
- Comparative analysis of early-onset and late-onset esophageal cancer burden in China, 1990-2021: based on the 2021 Global Burden of Disease Study.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Clinical predictors of early reflux and symptom severity after esophagectomy: a risk prediction tool.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- [A two-stage model for predicting postoperative pulmonary infection in esophageal cancer patients].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Article
- Outcomes of Curative Esophagectomy in Octogenarians vs. Non-Octogenarians with Esophageal Cancer: A Systematic Review and Meta-Analysis.Geriatrics (Basel, Switzerland) · 2026Review
- The global burden of non-communicable diseases attributable to behavioral risk factors and its trends from 1990 to 2021.Journal of advanced research · 2026Article
- Hyperspectral reconstruction of white light endoscopy images for enhanced segmentation of early esophageal lesions in patients.iScience · 2026Article
- Germline HLA-I genotypes predict pathologic response and survival outcomes in esophageal cancer patients undergoing neoadjuvant immunochemotherapy: a retrospective cohort study.World journal of surgical oncology · 2026Article
- IL-11-IL6ST-STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes.Scientific reports · 2026Article
- Long-term trends in disease burden of esophageal cancer in China and the forecast until 2050.BMC gastroenterology · 2026Article
- Apigenin Inhibits the Growth of Esophageal Squamous Cell Carcinoma (ESCC) Cells by Harnessing the Expression of MicroRNAs.Biomolecules · 2026Article
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
- Disease burden and prediction of liver cancer attributable to metabolic risks in five East Asian countries from 1990 to 2023.PloS one · 2026Article
- Development and Validation of an Interpretable Machine Learning Model Based on Peripheral Blood Biomarkers for Esophageal Cancer Risk Prediction.International journal of general medicine · 2026Article
- Exploring the role of adenosine deaminase in esophageal cancer and its potential for traditional Chinese medicine intervention.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectiveEsophageal cancer (EC) is the seventh most prevalent cancer globally and the sixth leading cause of cancer-related mortality. This study aimed to provide an updated stratified assessment of rates in EC incidence, mortality, and disability-adjusted life-years (DALYs) from 1990 to 2021 by sex, age, and Socio-demographic Index (SDI) at global, regional, and national levels, as well as to project the future trends of EC both globally and regionally.
methodsData about age-standardized rates (ASRs) of incidence (ASIR), mortality (ASDR), probability of death (ASPoD) and DALYs (ASDALYRs) of EC were obtained from the 2021 Global Burden of Disease (GBD) study. Estimated annual percentage changes (EAPCs) and average annual percentage changes (AAPC) were calculated over certain periods to describe the temporal trends of EC burdens. The analyses were disaggregated by sexes, GBD super-regions and regions, nations/territories, age-groups, and SDI quintiles. A Bayesian age-period-cohort (BAPC) model was constructed to project the global and regional EC ASRs in 2022-2035.
resultsDespite global reductions in EC ASRs, with ASIR, ASDR, and ASDALYR in 2021 of 6.65 [5.88, 7.45] (95% uncertainty interval), 6.25 [5.53, 7.00], and 148.56 [131.71, 166.82], decreasing by 24.9%, 30.7%, and 36.9% in 1990-2021, respectively, the absolute burden numbers were increased from 1990 to 2021, probably because of population growth and aging. Global newly diagnosed cases, deaths, and DALYs of EC increased to 576,529 [509,492, 645,648], 356,263 [319,363, 390,154], and 12,999,265 [11,522,861, 14,605,268] in 2021, by 62.53%, 51.18%, and 33.28% compared to records in 1990. The geographical pattern of EC was consistent: locations with the highest EC incidence and mortality rates were predominantly located in the Asian Esophageal Cancer Belt and African Esophageal Cancer Corridor, with East Asia, Southern Sub-Saharan Africa, and Eastern Sub-Saharan Africa as the GBD regions with the heaviest EC burdens, and Malawi, Eswatini, Mongolia, Zambia, and Zimbabwe with the most EC ASRs in 2021. However, owing to the population size, China, India, the United States, Japan, and Brazil had the heaviest absolute EC burdens. More pronounced alleviations of ASRs were observed in locations with high SDI levels, indicated by their lower AAPC values compared to those of low-SDI locations, while Sub-Saharan Africa regions had increasing EC ASRs, especially in Chad (114.76% in ASDR, for example), Sao Tome and Principe (97.93%), Togo (92.53%), Northern Mariana Islands (84.32%), Liberia (82.33%), etc. Smoking remained the leading contributor to EC ASDALYR globally and across most GBD super-regions in 2021. The EC burden is significantly heavier for males, with incidence and mortality in males in 2021 being 2.89 and 2.88 times higher, respectively, than in females. Across all age groups, EC posed an increasingly significant threat to men aged > 75 years. From 2022 to 2035, the ASR projections show only modest decrease in both global and regional EC burdens, and the absolute burden numbers are expected to increase globally and in nearly all GBD super-regions.
conclusionEC burden remains significant, with disparities across sexes, age groups, and regions. Region-specific and age-targeted measures are crucial to addressing these inequalities, especially in light of increasing EC burdens in older men and in African regions. Efforts should be taken in finding more solid attributions to risk factors for EC burdens and to better identify high-risk populations to inform targeted prevention and screening, and ultimately reduce the EC burden in an efficient and cost-effective way.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.